Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571922 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT00571922 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 72 participants.
The verdict
NCT00571922, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This clinical trial will compare 10 week treatment with acamprosate (2 gr/day) versus placebo, combined with weekly abstinence oriented individual counseling, in methamphetamine dependent patients, 72 subjects will be enrolled, with an interim analysis scheduled after 36 enrolled. Primary outcome is methamphetamine absitience over the 10 week treatment period, and the last 2 weeks of treatment. Abstinence is defined on a weekly basis as no urine positive of methamphetamine (or amphetamine) and self-report of not use for the 7 day period. Secondary measures include treatment retention, drug craving, mood, and safety.
Interventions
- DRUG placebo
- DRUG Acamprosate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571922
The ClinicalTrials.gov registry entry for NCT00571922 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00571922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571922 about?
NCT00571922 is a clinical study titled "A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction". This clinical trial will compare 10 week treatment with acamprosate (2 gr/day) versus placebo, combined with weekly abstinence oriented individual counseling, in methamphetamine dependent patients, 72 subjects will be enrolled, with an interim analysis scheduled after 36 enrolled. Primary outcome is...
What is the current status of trial NCT00571922?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2007-07. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00571922?
The interventions under investigation include: placebo (DRUG), Acamprosate (DRUG).
Who is sponsoring clinical trial NCT00571922?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.